These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 27831504)

  • 1. Industry corner: perspectives and controversies - The challenges of patient access to new medicines.
    Gann CN; Morsli N; Kaiser R
    Ann Oncol; 2017 Mar; 28(3):658-663. PubMed ID: 27831504
    [No Abstract]   [Full Text] [Related]  

  • 2. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report.
    Espinosa Bosch M; Asensi Diez R; García Agudo S; Clopes Estela A
    Farm Hosp; 2016 Jun; 40(4):316-27. PubMed ID: 27571499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
    Popat S; Mellemgaard A; Fahrbach K; Martin A; Rizzo M; Kaiser R; Griebsch I; Reck M
    Future Oncol; 2015; 11(3):409-20. PubMed ID: 25478720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
    Reck M; Mellemgaard A; von Pawel J; Gottfried M; Bondarenko I; Cheng Y; Zarogoulidis K; Luft A; Bennouna J; Barrueco J; Aboshady H; Hocke J; Kaiser R; Douillard JY;
    Lung Cancer; 2015 Nov; 90(2):267-73. PubMed ID: 26415992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line chemotherapy for non-small cell lung cancer: is more better or just simply more?
    Shepherd FA
    Lung Cancer; 2002 Jun; 36(3):309-11. PubMed ID: 12009243
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapeutic option after failure of first-line chemotherapy].
    Pneumologie; 2015 Apr; 69(4):245. PubMed ID: 26038780
    [No Abstract]   [Full Text] [Related]  

  • 7. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.
    Besse B; Soria JC; Le Chevalier T
    Ann Oncol; 2005 Jul; 16(7):997-8. PubMed ID: 15946975
    [No Abstract]   [Full Text] [Related]  

  • 9. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
    Kris MG; Millward M
    Semin Oncol; 1999 Jun; 26(3 Suppl 10):1-2. PubMed ID: 10437742
    [No Abstract]   [Full Text] [Related]  

  • 10. One more fallen star--ZODIAC and its implications.
    Stinchcombe TE; Govindan R
    Lancet Oncol; 2010 Jul; 11(7):604-5. PubMed ID: 20610317
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.
    Wachters FM; Groen HJ; Biesma B; Schramel FM; Postmus PE; Stigt JA; Smit EF
    Br J Cancer; 2005 Jan; 92(1):15-20. PubMed ID: 15597104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epiphora induced by intermittent docetaxel (taxotere) in patients with non-small cell lung cancer.
    Spell DW; Estephan FF; Lin JT; Jones DV
    Cancer Invest; 2003; 21(4):550-2. PubMed ID: 14533445
    [No Abstract]   [Full Text] [Related]  

  • 13. [Successful chemotherapy with carboplatin and docetaxel for an elderly patient with advanced non-small cell lung cancer].
    Kawashima S; Kawashima T; Kuroda T; Kikkawa K; Nishi Y; Tanabe M; Gotou T; Matsuzawa Y; Shirai K
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):493-5. PubMed ID: 16612159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers.
    Hortobagyi GN; Kris MG
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):1-3. PubMed ID: 12170444
    [No Abstract]   [Full Text] [Related]  

  • 15. Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.
    Okamoto I; Miyazaki M; Takeda M; Terashima M; Azuma K; Hayashi H; Kaneda H; Kurata T; Tsurutani J; Seto T; Hirai F; Konishi K; Sarashina A; Yagi N; Kaiser R; Nakagawa K
    J Thorac Oncol; 2015 Feb; 10(2):346-52. PubMed ID: 25299232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimize toxicity or preserve efficacy? A delicate trade-off in the management of older patients with lung cancer.
    Owonikoko TK; Ramalingam SS
    J Clin Oncol; 2015 Feb; 33(6):534-6. PubMed ID: 25584000
    [No Abstract]   [Full Text] [Related]  

  • 17. Study shows 2-year survival advantage for docetaxel.
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):323-4. PubMed ID: 12113094
    [No Abstract]   [Full Text] [Related]  

  • 18. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.
    Syrios J; Nintos G; Georgoulias V
    Expert Rev Anticancer Ther; 2015; 15(8):875-84. PubMed ID: 26204906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer--experience from a prematurely closed phase II study.
    Raez LE; Rosado MF; Santos ES; Reis IM
    Lung Cancer; 2004 Jul; 45(1):131-2. PubMed ID: 15196746
    [No Abstract]   [Full Text] [Related]  

  • 20. The development of docetaxel (Taxotere) in non-small cell lung cancer.
    Kris MG; Miller VA; Ng KK; Grant SC
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-1-S14-4. PubMed ID: 9335515
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.